Navigation Links
AVI BioPharma Reports Positive Pre-Clinical Influenza Data

e. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2). AVI's potential treatment for seasonal influenza A will be made available to potential licensees.

About Influenza A Viruses

Influenza, or flu, is a contagious respiratory illness caused by influenza viruses. On average 5 percent to 20 percent of the U.S. population is infected with the flu each year. Influenza A virus is an enveloped negative-strand RNA virus, with eight genome segments that code for 10 proteins. Influenza strains are subtyped according to the antigenic and genetic nature of their surface glycoproteins: hemagglutinin (HA or H) and neuraminidase (NA or N). Fifteen H and nine N subtypes have been identified, with three associated with widespread human disease (H1N1, H2N2 and H3N2). In addition, several subtypes of avian influenza virus -- H5N1, H7N7 and H9N2 -- can infect and cause disease in humans.

The current influenza pandemic in birds throughout Asia, Eastern Europe and Turkey is caused by the H5N1 subtype. It is thought that co-infection of humans or certain animals (such as pigs) with both H1N1 and H5N1 can lead to a reassortment or recombination of viral particles, resulting in the emergence of a virus with dangerous public health properties, namely one to which the human population has no natural immunity and which has the ability to spread easily from person to person. It is believed that emergence of avian flu by this general mechanism may have led to the worldwide pandemics of 1918, 1957 and 1968.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is design
'"/>




Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AVI BioPharma Reports Positive Pre Clinical Influenza Data
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... Board of Directors has authorized the implementation of a 1:25 ... be completed on or before January 15, 2012. ... by the Company,s stockholders at a November 4, 2011, special ...
... EXTON, Pa., Jan. 3, 2012 ViroPharma Incorporated (Nasdaq: ... Julie H. McHugh to its board of directors. ... health care industry experience and leadership to ViroPharma,s Board ... of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company.  ...
Cached Medicine Technology:Radient Pharmaceuticals Announces Reverse Stock Split 2ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors 2
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... , ... LLP (ENTA) announced today that it has expanded the implementation of its state-of-the-art Electronic Medical ... City, Long Island, Westchester, Rockland, Putnam and Orange Counties and northern New Jersey. All of ... ...
... ... Department of Corrections , ... Miami, FL (PRWEB) July 1, 2010 -- JPay.com, the Trusted Leader in ... million offenders nationwide with absolutely no cost to correctional departments and today announced the ...
... ... the release of their new Alpha 3C™ formula, designed to naturally support focus, ... ... provider of premium dietary supplements, announces the release of their new Alpha 3C™ ...
... that older adults commonly have low vitamin D levels and ... the metabolic syndrome, a condition that affects one in four ... Annual Meeting in San Diego. "Because the metabolic syndrome ... vitamin D level in the body might be important in ...
... men with higher testosterone levels are more likely to ... the future. The results were presented at The Endocrine ... study finding contradicts smaller studies that have shown that ... cardiovascular disease," said presenting author Kristen Sueoka, MD, a ...
... ... Marijuana emerges as the most popular plant in the United States we,re still ... Casias is a perfect example of the discrimination as at the young age ... been forced to fight Wal-Mart after losing his job for using medicinal marijuana ...
Cached Medicine News:Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 2Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 3Health News:JPay, the Apple of Washington State DOC's eye 2Health News:Purity Products Releases Alpha 3C 2Health News:Low vitamin D linked to the metabolic syndrome in elderly people 2Health News:Higher testosterone may raise risk of heart disease in elderly men 2Health News:Fired Wal-Mart Employee Accepts Full Scholarship to The Medical Marijuana Academy 2
... O.R. Special Protective Apron is made ... and a sterile gown. Uniquely it ... sterile field. Reaching through the back ... are released, and the protective apron ...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... coat apron, weight is distributed uniformly ... comfortable wear without fatigue. Made to ... front closing special procedure apron comes ... that make it a cinch to ...
... Wolfs Easy Wrap Apron has always ... easy to put-on, adjust and take-off. Our ... new Easy sures Wrap features two velcro ... The attached Thyroid collar adjusted to fully ...
Medicine Products: